The FDA approved relacorilant, Corcept Therapeutics' glucocorticoid receptor antagonist, in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic regimens including bevacizumab. This decision came about 2.5 months ahead of the agency's goal date and was based on the pivotal Phase 3 ROSELLA trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.